Developer docs
API playgroundTry for free, no card

Search company profiles

Coriell Life Sciences

Full company profile

uuid000225l

Namestring
Coriell Life Sciences
Legal namestring
Coriell Life Sciences
Websiteurl
coriell.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Coriell Life Sciences was a Philadelphia-based pharmacogenomics (PGx) clinical decision support software company founded in 2013 that developed evidence-based tools translating genetic test results into prescribing guidance. The company's core product analyzed 17 genes and 4 HLA alleles to help healthcare providers understand individual genetic responses to medications and optimize prescribing decisions, with primary therapeutic focus in psychiatry, cardiology, and oncology — areas with elevated adverse drug reaction risk. The technology addressed the trial-and-error nature of prescribing by layering pharmacogenomic interpretation onto existing clinical workflows.

The company operated as a B2B enterprise technology provider, distributing its decision support tools through OEM/embedded licensing agreements with healthcare and diagnostics partners. Its flagship relationship was with Quest Diagnostics, which launched a national pharmacogenomics testing service in September 2025 incorporating Coriell's clinical decision support layer. Revenue was generated through licensing and royalty arrangements rather than direct provider sales, and pricing was not publicly disclosed. CEO Scott Megill and co-founder Joseph P. Jarvis led the organization through its pre-acquisition period.

In September 2025, Coriell Life Sciences was acquired by InformedDNA, combining its PGx capabilities with InformedDNA's genetics expertise and technology platform and ending Coriell's independent operating history. The company had raised approximately $9.5 million in disclosed funding (2019) plus a follow-on round (2021) and employed 51–100 people at the time of acquisition. Note: Coriell Life Sciences is distinct from the Coriell Institute for Medical Research (coriell.org), an unrelated biobanking and research services organization; available sources do not clarify any ownership or operational linkage between the two entities.

Short descriptiontext

Coriell Life Sciences is a Philadelphia-based pharmacogenomics company that develops clinical decision support software analyzing 17 genes and 4 HLA alleles to optimize medication prescribing across psychiatry, cardiology, and oncology for healthcare providers and diagnostics partners.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
pharmacogenomics software, clinical decision support, precision medicine, genetic testing analysis, medication optimization
Industry2 codes
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAAANAE
Clinical Decision Support & Workflow Integration (EHR/oncology systems)
NAICS code1 code
  • Other Scientific and Technical Consulting Services54169
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmacogenomics Clinical Decision Support Software
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Decision Support Licensing
TypeLicensing Royalties
Description

Coriell Life Sciences generated revenue by providing pharmacogenomics clinical decision support technology that was integrated into healthcare providers' systems and diagnostic services. The technology analyzed genes and HLA alleles to help optimize medication prescribing decisions.

clpmag.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Coriell Life Sciences provides pharmacogenomics-powered clinical decision support tools that help healthcare providers interpret a patient's genetic profile and optimize medication prescribing decisions. The technology analyzes specific genes and HLA alleles to predict individual drug response, with applications across psychiatry, cardiology, and oncology specialties. The offering is delivered primarily through enterprise licensing arrangements that embed the decision support into larger diagnostic and clinical workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Adverse drug reactions are the fourth leading cause of death in the United States
Product overview1 text field

Coriell Life Sciences (now part of InformedDNA following acquisition) offered pharmacogenomics-focused clinical decision support tools. The company's core product provided genetic testing interpretation capabilities that analyze how individual genetic variations affect medication response, enabling personalized medication guidance across multiple therapeutic areas including psychiatry, cardiology, and oncology.

Product and service1 record
1Clinical Decision Support Tools for Pharmacogenomics
CategoryClinical Decision Support Software
Description

Evidence-based clinical decision support software that interprets pharmacogenomic test results, analyzing 17 genes and 4 HLA alleles, to guide medication selection and dosing across psychiatry, cardiology, and oncology. Licensed to enterprise diagnostics providers for embedding in their pharmacogenomics testing services.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-09
Description

Quest Diagnostics launched a pharmacogenomics testing service that incorporated clinical decision support tools powered by Coriell Life Sciences. The service analyzes 17 genes and 4 HLA alleles to help healthcare providers optimize prescribing decisions across psychiatry, cardiology, and oncology specialties.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Coriell Life Sciences was acquired by InformedDNA in 2025. The acquisition combined Coriell Life Sciences' pharmacogenomics capabilities with InformedDNA's genetics expertise and technology platform, strengthening InformedDNA's position in the precision medicine space.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Illumina is a foundational sequencing and genomics-infrastructure provider whose technology underpins most PGx and clinical-genomics workflows. It is an enabling/adjacent peer rather than a direct competitor, but shapes the ecosystem in which Coriell's CDS operates.

TypeDirect peer
Description

Molecular Health provides a precision-medicine clinical decision support platform that analyzes genomic data to guide therapy selection, particularly in oncology. It overlaps directly with Coriell's CDS approach, especially in oncology pathways.

TypeDirect peer
Description

YouScript (by Genelex) delivers pharmacogenomic testing with an interactive clinical decision support platform that flags drug-gene interactions for prescribers. It is a direct competitor in the embedded PGx CDS software category.

TypeBroad incumbent
Description

Quest Diagnostics is both Coriell's enterprise customer (embedded into its PGx testing service) and a broad incumbent offering its own pharmacogenomic and genetic testing menu. It is the most direct commercial-partner comparable and a competitive threat at the lab-services layer.

TypeBroad incumbent
Description

Myriad Genetics offers genetic and pharmacogenomic testing products with associated decision-support reports across multiple therapeutic areas. It is a broad incumbent in the same clinical-genomics category with overlapping oncology and psychiatry content.

TypeDirect peer
Description

Genomind provides pharmacogenomic testing and decision support specifically focused on mental health / psychiatry prescribing. It competes head-to-head with Coriell's psychiatry-focused PGx CDS capabilities and uses a similar gene-panel + clinician-facing report model.

TypeBroad incumbent
Description

InformedDNA is a genetics-services and counseling organization that acquired Coriell Life Sciences in September 2025. Post-acquisition it is the corporate parent combining Coriell's PGx CDS with its own genetics-services platform, making it both parent and a broadened precision-medicine peer.

TypeDirect peer
Description

OneOme offers the RightMed pharmacogenomic test with integrated clinical decision support to help providers optimize medication selection. It is a direct functional peer to Coriell's PGx CDS platform, competing for the same provider and lab-partner channels.

TypeBroad incumbent
Description

Invitae provides clinical genetic testing across many specialties with structured clinician reports that serve a decision-support function. It is a broader incumbent in clinical genomics that overlaps with Coriell's specialty coverage model.

TypeDirect peer
Description

2bPrecise delivers a precision-medicine CDS layer that integrates genomic and pharmacogenomic insights into EHR workflows. It competes for the same embedded/EHR-integrated CDS slot that Coriell's tools target.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Coriell Life Sciences

Pharmacogenomics Clinical Decision Support Softwarecoriell.com

Coriell Life Sciences is a Philadelphia-based pharmacogenomics company that develops clinical decision support software analyzing 17 genes and 4 HLA alleles to optimize medication prescribing across psychiatry, cardiology, and oncology for healthcare providers and diagnostics partners.

What Coriell Life Sciences does

Coriell Life Sciences was a Philadelphia-based pharmacogenomics (PGx) clinical decision support software company founded in 2013 that developed evidence-based tools translating genetic test results into prescribing guidance. The company's core product analyzed 17 genes and 4 HLA alleles to help healthcare providers understand individual genetic responses to medications and optimize prescribing decisions, with primary therapeutic focus in psychiatry, cardiology, and oncology — areas with elevated adverse drug reaction risk. The technology addressed the trial-and-error nature of prescribing by layering pharmacogenomic interpretation onto existing clinical workflows.

The company operated as a B2B enterprise technology provider, distributing its decision support tools through OEM/embedded licensing agreements with healthcare and diagnostics partners. Its flagship relationship was with Quest Diagnostics, which launched a national pharmacogenomics testing service in September 2025 incorporating Coriell's clinical decision support layer. Revenue was generated through licensing and royalty arrangements rather than direct provider sales, and pricing was not publicly disclosed. CEO Scott Megill and co-founder Joseph P. Jarvis led the organization through its pre-acquisition period.

In September 2025, Coriell Life Sciences was acquired by InformedDNA, combining its PGx capabilities with InformedDNA's genetics expertise and technology platform and ending Coriell's independent operating history. The company had raised approximately $9.5 million in disclosed funding (2019) plus a follow-on round (2021) and employed 51–100 people at the time of acquisition. Note: Coriell Life Sciences is distinct from the Coriell Institute for Medical Research (coriell.org), an unrelated biobanking and research services organization; available sources do not clarify any ownership or operational linkage between the two entities.

Coriell Life Sciences firmographics

Firmographics
Name
Coriell Life Sciences
Legal name
Coriell Life Sciences
Website
https://coriell.com
Company type
Private
Founded year
2013
Operating status
Acquired
Headcount range
1–10 employees
Short description
Coriell Life Sciences is a Philadelphia-based pharmacogenomics company that develops clinical decision support software analyzing 17 genes and 4 HLA alleles to optimize medication prescribing across psychiatry, cardiology, and oncology for healthcare providers and diagnostics partners.
Ownership category
akta.pro rank

Coriell Life Sciences industry classification

Industry
Product category
Pharmacogenomics Clinical Decision Support Software
NAICS
Other Scientific and Technical Consulting Services (54169)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAAANAE
Clinical Decision Support & Workflow Integration (EHR/oncology systems)

Keywords

  • Pharmacogenomics software
  • Clinical decision support
  • Precision medicine
  • Genetic testing analysis
  • Medication optimization

Where Coriell Life Sciences is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Markets served

Coriell Life Sciences business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Clinical Decision Support Licensing: Coriell Life Sciences generated revenue by providing pharmacogenomics clinical decision support technology that was integrated into healthcare providers' systems and diagnostic services. The technology analyzed genes and HLA alleles to help optimize medication prescribing decisions.

Go-to-market motion1 record

Distribution channels1 record

Coriell Life Sciences product offering

Product offering

Core offering

Coriell Life Sciences provides pharmacogenomics-powered clinical decision support tools that help healthcare providers interpret a patient's genetic profile and optimize medication prescribing decisions. The technology analyzes specific genes and HLA alleles to predict individual drug response, with applications across psychiatry, cardiology, and oncology specialties. The offering is delivered primarily through enterprise licensing arrangements that embed the decision support into larger diagnostic and clinical workflows.

Product overview

Coriell Life Sciences (now part of InformedDNA following acquisition) offered pharmacogenomics-focused clinical decision support tools. The company's core product provided genetic testing interpretation capabilities that analyze how individual genetic variations affect medication response, enabling personalized medication guidance across multiple therapeutic areas including psychiatry, cardiology, and oncology.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Decision Support Tools for Pharmacogenomics Evidence-based clinical decision support software that interprets pharmacogenomic test results, analyzing 17 genes and 4 HLA alleles, to guide medication selection and dosing across psychiatry, cardiology, and oncology. Licensed to enterprise diagnostics providers for embedding in their pharmacogenomics testing services.

Quantifiable outcome

  • Adverse drug reactions are the fourth leading cause of death in the United States

Companies that use Coriell Life Sciences

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Coriell Life Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Coriell Life Sciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Quest DiagnosticscoreStrategic or Co-development Partner · 9 September 2025Quest Diagnostics launched a pharmacogenomics testing service that incorporated clinical decision support tools powered by Coriell Life Sciences. The service analyzes 17 genes and 4 HLA alleles to help healthcare providers optimize prescribing decisions across psychiatry, cardiology, and oncology specialties.
  • InformedDNAcoreStrategic or Co-development Partner · 1 January 2025Coriell Life Sciences was acquired by InformedDNA in 2025. The acquisition combined Coriell Life Sciences' pharmacogenomics capabilities with InformedDNA's genetics expertise and technology platform, strengthening InformedDNA's position in the precision medicine space.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Coriell Life Sciences competitors and assessment

Company assessment

Others

  • Illumina: Illumina is a foundational sequencing and genomics-infrastructure provider whose technology underpins most PGx and clinical-genomics workflows. It is an enabling/adjacent peer rather than a direct competitor, but shapes the ecosystem in which Coriell's CDS operates.

Direct peers

  • Molecular Health: Molecular Health provides a precision-medicine clinical decision support platform that analyzes genomic data to guide therapy selection, particularly in oncology. It overlaps directly with Coriell's CDS approach, especially in oncology pathways.
  • YouScript (Genelex): YouScript (by Genelex) delivers pharmacogenomic testing with an interactive clinical decision support platform that flags drug-gene interactions for prescribers. It is a direct competitor in the embedded PGx CDS software category.
  • Genomind: Genomind provides pharmacogenomic testing and decision support specifically focused on mental health / psychiatry prescribing. It competes head-to-head with Coriell's psychiatry-focused PGx CDS capabilities and uses a similar gene-panel + clinician-facing report model.
  • OneOme: OneOme offers the RightMed pharmacogenomic test with integrated clinical decision support to help providers optimize medication selection. It is a direct functional peer to Coriell's PGx CDS platform, competing for the same provider and lab-partner channels.
  • 2bPrecise (EHR-cone Healthspinout / Exact Sciences): 2bPrecise delivers a precision-medicine CDS layer that integrates genomic and pharmacogenomic insights into EHR workflows. It competes for the same embedded/EHR-integrated CDS slot that Coriell's tools target.

Broad incumbents

  • Quest Diagnostics: Quest Diagnostics is both Coriell's enterprise customer (embedded into its PGx testing service) and a broad incumbent offering its own pharmacogenomic and genetic testing menu. It is the most direct commercial-partner comparable and a competitive threat at the lab-services layer.
  • Myriad Genetics: Myriad Genetics offers genetic and pharmacogenomic testing products with associated decision-support reports across multiple therapeutic areas. It is a broad incumbent in the same clinical-genomics category with overlapping oncology and psychiatry content.
  • InformedDNA: InformedDNA is a genetics-services and counseling organization that acquired Coriell Life Sciences in September 2025. Post-acquisition it is the corporate parent combining Coriell's PGx CDS with its own genetics-services platform, making it both parent and a broadened precision-medicine peer.
  • Invitae: Invitae provides clinical genetic testing across many specialties with structured clinician reports that serve a decision-support function. It is a broader incumbent in clinical genomics that overlaps with Coriell's specialty coverage model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Coriell Life Sciences social profiles

Digital presence

Coriell Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Coriell Life Sciences leadership team

Management profile

Number of profiles

Profiles1 record

Coriell Life Sciences funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Coriell Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coriell Life Sciences

What does Coriell Life Sciences do?

Coriell Life Sciences provides pharmacogenomics-powered clinical decision support tools that help healthcare providers interpret a patient's genetic profile and optimize medication prescribing decisions. The technology analyzes specific genes and HLA alleles to predict individual drug response, with applications across psychiatry, cardiology, and oncology specialties. The offering is delivered primarily through enterprise licensing arrangements that embed the decision support into larger diagnostic and clinical workflows.

When was Coriell Life Sciences founded?

Coriell Life Sciences was founded in 2013. It employs 1 to 10 people.

Where is Coriell Life Sciences based?

Coriell Life Sciences is headquartered in Philadelphia, United States, in the North America region.

How does Coriell Life Sciences make money?

One revenue line is on record: clinical Decision Support Licensing.

Who are Coriell Life Sciences's main competitors?

Illumina is listed as an others. Direct peers are Molecular Health, YouScript (Genelex), Genomind, OneOme and 2bPrecise (EHR-cone Healthspinout / Exact Sciences). Broad incumbents are Quest Diagnostics, Myriad Genetics, InformedDNA and Invitae.

Does Coriell Life Sciences have an API?

No public API is recorded for Coriell Life Sciences.

What industry is Coriell Life Sciences in?

Coriell Life Sciences's product category is Pharmacogenomics Clinical Decision Support Software. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLAAANAE, Clinical Decision Support & Workflow Integration (EHR/oncology systems). Its NAICS code is 54169 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizInformedDNA Acquires Coriell Life SciencesInformedDNA acquired Coriell Life Sciences, a pharmacogenomics and clinical decision support provider. The acquisition integrates Coriell's services into InformedDNA's DNAimpact platform, expanding access to genetic insights. Coriell CEO Scott Megill will become InformedDNA's Chief Commercial Officer.GlobeNewswireInformedDNA Acquires Coriell Life Sciences, Expanding Precision Health CapabilitiesInformedDNA acquired Coriell Life Sciences, a pharmacogenomic services provider, to expand its precision health capabilities. The integration adds Coriell's Corigen medication risk management program and research analysis to InformedDNA's DNAimpact platform. Coriell CEO Scott Megill will become InformedDNA's Chief Commercial Officer.Healthcare DiveInformedDNA Acquires Coriell Life Sciences, Expanding Precision Health CapabilitiesInformedDNA acquired Coriell Life Sciences, a pharmacogenomic services provider, to expand precision health capabilities. The integration adds Coriell's Corigen medication risk management program and research analysis to InformedDNA's DNAimpact platform. Coriell CEO Scott Megill will become InformedDNA's Chief Commercial Officer.The Manila TimesInformedDNA Acquires Coriell Life Sciences, Expanding Precision Health CapabilitiesInformedDNA acquired Coriell Life Sciences, adding its pharmacogenomics services to its genetic test interpretation and counseling. The integration expands patient access to personalized treatment decisions and reduces healthcare costs. Coriell's CEO Scott Megill will become InformedDNA's Chief Commercial Officer.Business InsiderInformedDNA Acquires Coriell Life Sciences, Expanding Precision Health CapabilitiesInformedDNA acquired Coriell Life Sciences, a pharmacogenomic services provider, to expand precision health capabilities. Coriell's Corigen program and research analysis will integrate into InformedDNA's DNAimpact platform, and Coriell CEO Scott Megill will become InformedDNA's Chief Commercial Officer.GlobeNewswireInformedDNA Acquires Coriell Life Sciences, Expanding Precision Health CapabilitiesInformedDNA acquired Coriell Life Sciences, a pharmacogenomic services provider, to expand its precision health capabilities. The acquisition integrates Coriell's services into InformedDNA's DNAimpact platform, and Coriell CEO Scott Megill will become InformedDNA's Chief Commercial Officer.HIT ConsultantInformedDNA Acquires Coriell Life SciencesInformedDNA acquired Coriell Life Sciences, a pharmacogenomic services provider, with financial terms undisclosed. The acquisition expands InformedDNA's precision health platform, DNAimpact, to offer broader genetic insights for personalized treatment decisions.InformeddnaInformedDNA Acquires Coriell Life Sciences, Expanding Precision Health Capabilities – InformedDNAInformedDNA, a precision health company based in St. Petersburg, Florida, acquired Coriell Life Sciences, a Philadelphia-based provider of pharmacogenomic services and clinical decision support, on March 19, 2025. The acquisition combines InformedDNA's genetic test interpretation and counseling capabilities with Coriell Life Sciences' pharmacogenomics expertise to enable more personalized medication and treatment decisions for patients. Coriell Life Sciences CEO Scott Megill will transition to the role of Chief Commercial Officer at InformedDNA following the deal.YahooQuest Diagnostics (DGX) Partners to Offer New Testing ServiceQuest Diagnostics partnered with Coriell Life Sciences to offer pharmacogenomics testing to select medical plan members. The voluntary, no-cost DNA test analyzes drug reactions and provides personalized recommendations. The pharmacogenomics market is projected to grow from $6.15 billion in 2022 to $12 billion by 2030.PR NewswireNatural Symptoms of Aging or Medication Side Effects?Coriell Life Sciences published peer-reviewed research in the Cureus Journal of Medical Science showing that symptoms commonly attributed to aging—such as fatigue, dizziness, and confusion—may actually be adverse drug reactions driven by an individual's DNA. The case study followed a 71-year-old woman whose pharmacogenomic analysis revealed two clinically significant genetic interactions with her medication regimen, leading to changes that improved her energy levels and reduced leg pain. The company positions this as a demonstration of how precision medicine can reduce healthcare costs and improve quality of life for aging populations.